A typical vaccine stimulates a person’s immune system, yet only a portion of the immune response actually targets the disease it’s designed to protect against. However, a new technology may be changing that dynamic.
In this episode, I sit down with Lou Reese, an entrepreneur who has led or co-founded several biotech companies and has been working on synthetic peptide-based active immunotherapy medicines. He’s co-CEO of United Biomedical and co-founder of Vaxxinity, Cana Life, and Axxium.
He’s working on a product that could—if proven successful—transform our approach to treating and preventing Alzheimer’s. He and his team also have a product that has shown preliminary promise in phase 1 trials in treating Parkinson’s.
In this episode, he also reveals an incredible story: He and his team previously developed a peptide-based active immunotherapy vaccine candidate for COVID-19, and they successfully completed Phase 1 and Phase 2 trials. Institutional backing, however, favored Pfizer and Moderna. In 2022, Lou Reese’s team was invited to the White House “Summit on the Future of COVID‑19 Vaccines,” where they presented their candidate as an alternative to Pfizer’s mRNA vaccine, which by then had been associated with serious side effects.
In the end, their product was never approved, and related content on YouTube was marked as misinformation.
Views expressed in this video are opinions of the host and the guest, and do not necessarily reflect the views of The Epoch Times.
